This is an international site for AFINITOR^® (everolimus) and is intended for Health Care Professionals outside the U.S. The information on the site is not country-specific, and may contain information that is outside the approved indications in the country in which you are located. Please contact your local Novartis representative for the latest information specific to your country

Welcome to the Afinitor Product Website

AFINITOR is approved for use in 73 countries around the world.

AFINITOR Country-Level Websites

Below is a list of the countries that host a AFINITOR website based on local label and in local language. They are intended for Health Care Professional (HCPs) only. If you are a HCP from one of the countries listed below, click on your country link to be redirected to your country AFINITOR website.

AFINITOR International Website

This website is intended for Health Care Professionals (HCPs) outside the U.S. The information on this website is not country specific and may contain information that is outside the approved indication in the country in which you are located. Please contact your local representative for local prescribing information via www.novartisoncology.com/contactus.

IMPORTANT: The information on this website is based on the European Summary of Product Characteristics (EUSmPC)

Afinitor International Website | For International Healthcare Professionals Only | US Residents

AFINITOR is indicated for the treatment of hormone receptor-positive, HER2/neu negative advanced breast cancer, in combination with exemestane, in postmenopausal women without symptomatic visceral disease after recurrence or progression following a nonsteroidal aromatase inhibitor.

AFINITOR is indicated for the treatment of unresectable or metastatic, well-or moderately-differentiated neuroendocrine tumours of pancreatic origin in adults with progressive disease.

AFINITOR is a once-daily oral inhibitor of mTOR (mammalian target of rapamycin) for patients with advanced renal cell carcinoma (RCC) whose disease has progressed on or after treatment with VEGF-targeted therapy.